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Saga, Japan.c-Aminobutyric acid type A (GABAA) receptor b1 (gabrb1), a subunit of GABAA receptors involved in
inhibitory effects on neurotransmission, was found to associate with the formation of protease-
resistant prion protein in prion-infected neuroblastoma cells. Silencing of gabrb1 gene expression
signiﬁcantly decreased the abnormal prion protein level but paradoxically increased the normal
prion protein level. Treatment with a gabrb1-speciﬁc inhibitor, salicylidene salicylhydrazide,
dose-dependently decreased the abnormal prion protein level, but silencing of other GABAA recep-
tor subunits’ gene expression and treatments with the receptor antagonists and agonists did not.
Therefore, gabrb1 involvement in abnormal prion protein formation is independent of GABAA
receptors.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction sible linkage of c-aminobutyric acid A receptor b1 (gabrb1) withTransmissible spongiform encephalopathies or prion diseases
are fatal neurodegenerative disorders that include Creuzfeldt–
Jakob disease in humans, and bovine spongiform encephalopathy
and scrapie in animals. These diseases are characterized by deposi-
tion of a partially protease-resistant abnormal isoform of prion
protein (PrPres), which is the main component of the pathogen
and which is converted from the normal cellular isoform of prion
protein (PrPc) in the central nervous system and lymphoreticular
system [1]. Cell biology of the biosynthesis and metabolism of PrPc
and PrPres has been eagerly investigated in prion-infected cells
[2,3] but has not been fully elucidated. Especially, endogenous fac-
tors involved in the formation of PrPres or the conformational
change from PrPc into PrPres [4,5] remain enigmatic.
Using gene screening by the gene silencing technique with
small interfering RNA (siRNA) or short hairpin RNA (shRNA) [6,7],
we have sought endogenous factors affecting the metabolism of
PrPres in prion-infected neuroblastoma cells. We report here a pos-chemical Societies. Published by E
Prion Research, Tohoku Uni-
i, Aoba-ku, Sendai 980-8575,
. Doh-ura).
niversity School of Medicine,the formation of PrPres. In fact, gabrb1 is a subunit of c-aminobu-
tyric acid type A (GABAA) receptors responsible for most of the fast
inhibitory synaptic transmission in mammalian brain [8]. Belong-
ing to the ligand-gated ion channels, they are formed by the pen-
tameric assembly of homologous subunits. Numerous GABAA
receptor subunits have been identiﬁed (a16, b13, c13, d, p,
e, and h), all of which are products of separate genes, and most GA-
BAA receptors contain two a subunits, two b subunits and either
one c subunit or one d subunit [8]. It has been well documented
that GABAergic neurons are affected by prion infection [9–15],
but it is not clear whether GABAA receptors are involved in PrPres
formation. Therefore, to address this query, we performed gene
silencing experiments for gabrb1 and other representative GABAA
receptor subunits (a5, b3, c2, and d) as well as GABAA receptor
modulating experiments using the antagonists and agonists in
prion-infected cells.2. Materials and methods
2.1. siRNAs and compounds
Double-stranded siRNAs for GABAA receptor subunits used
for this study (Table 1) were purchased from Invitrogen Corp.
(Carlsbad, CA, USA). Some GABAA receptor antagonists (bicucullinelsevier B.V. All rights reserved.
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isoguvacine hydrochloride) were purchased from Sigma–Aldrich
Corp. (St. Louis, MO, USA). Another agonist, pentobarbital, was pur-
chased as a 5% (approximately 200 mM) solution of its sodium salt,
nembutal, from Dainippon Sumitomo Pharma Co. Ltd. (Osaka,
Japan). A speciﬁc inhibitor of GABAA receptor b1 subunit, salicylid-
ene salicylhydrazide, was obtained from Tocris Bioscience (Mis-
souri, USA).
2.2. shRNA expression vectors
The DNA fragments ﬂanking 50 BamHI recognition sequence and
30 HindIII recognition sequence, which corresponded to shRNA se-
quences for GABAA receptor subunits, were produced by annealing
pairs of sense and antisense 64mer oligonucleotides, of which
sense sequences were designed as follows: 50-GATCCGAg-
GGTGGAGTTCAtAAtAGGCTTCCTGTCACCTGTTGTGAACTCCACCTTC-
TTTTTTA-3’ targeting to nucleotides 663–683 of b1 subunit coding
sequence; 50-GATCCACCTGGTgTGAtAGAtGTTTGCTTCCTGTCACAA-
ACGTCTGTCATACCAGGTTTTTTTA-30 targeting to nucleotides 355–
375 of c2 subunit coding sequence; 50-GATCCGAATGGGCTgCTT-
tACtATCCCTTCCTGTCAGGATGGTGAAGTAGCCCATTCTTTTTTA-30 tar-
geting to nucleotides 809–829 of c2 subunit coding sequence;
50-GATCCACATGGAgTACACtATGAtTGCTTCCTGTCACAGTCATGGTG-
ATTTCCATGTTTTTTTA-30 targeting to nucleotides 245–265 of d
subunit coding sequence. Bold italic letters and small bold italic
letters, respectively denote target sites and mismatch-induced
sites. The DNA fragments were ligated into a pBAsi-hH1 (Takara
Bio Inc., Shiga, Japan) cut with BamHI and HindIII. The ligated vec-
tors were introduced into Escherichia coli; then plasmids of interest
were harvested and sequenced.
2.3. Mutated gabrb1 expression vector
Mouse gabrb1 gene was cloned from a ready mouse brain cDNA
library (Marathon; Takara Bio Inc.) using PCR with KOD-plus DNA
polymerase (Toyobo Co. Ltd., Osaka, Japan). A PCR product was in-
serted into a pcDNA3.1 Myc/His expression vector (Invitrogen
Corp.). The ligated vectors were introduced into E. coli; then plas-
mids of interest were harvested and sequenced. Mutations were
induced by site-directed mutagenesis using PCR technique with
primers of 50-GATGCATCTGCAGCgcGtGTgGCtCTtGGtATaACaAC-
GGTGCTG-30 (small italic letters indicate silent mutations induced)
and 50-TGCAGATGCATCATAGTTGATCCA-30. The PCR products were
treated with DpnI for digesting template plasmids and introduced
directly into E. coli; then plasmids of interest were harvested and
sequenced.
2.4. Gene silencing experiments
Mouse neuroblastoma N2a cells infected persistently with RML
prion strain (ScN2a) or 22L prion strain (N167) were diluted to 10%Table 1
siRNAs and shRNAs used for this study.
GABAA receptor subunit
examined
Nucleotide position of target region*
siRNA (catalog no.**) shRNA
a5 311–335 (MSS201426)
b1 820–844 (MSS204523) 663–683
b3 873–897 (MSS204527)
b3 transcript variant 1 62–86 (MSS204528)
c2 355–375, 809–829
d 245–265
* Nucleotide position in the coding sequence of each GABAA receptor subunit gene.
** siRNAs were obtained from Invitrogen Corp. (Carlsbad, CA, USA).or 15% conﬂuence with Opti MEM I (Invitrogen Corp.) including
10% fetal bovine serum (FBS), and 2.4 ml each was seeded onto
six-well plates. Transfection was performed on the next day of
seeding. TransFectin (3.0 ll/well; Bio-Rad Laboratories, Inc., Hercu-
les, CA, USA) was used for the transfection of shRNA expression
vectors, and siLentFect (3.0 ll/well, Bio-Rad Laboratories, Inc.)
was used for transfection of double-stranded siRNAs. The amounts
of vectors or siRNAs used in transfection were, respectively, 0.2 lg
per well or 20 nM per well. Medium was changed on the day after
transfection. Cells were harvested after washing with PBS 3 days
after transfection.
2.5. Rescue experiment
The ScN2a cells were diluted to 15% conﬂuence with Opti MEM I
including 10% FBS, and 2 ml each was seeded onto six-well plates.
Transfection was performed on the day after seeding. TransFectin
(2.0 ll/well) was used for the transfection of both mutated gabrb1
expression vector and double-stranded siRNA. The amounts of the
vector and the siRNA used for transfection were, respectively,
0.8 lg per well and 5 nM per well. Medium was changed on the
day after transfection. Cells were harvested after washing with
PBS 3 days after transfection.
2.6. Immunoblotting
Cells were lysed with lysis buffer (0.5% sodium deoxycholate,
0.5% Nonidet P-40, PBS) after rinsed with PBS, and debris was elim-
inated by centrifugation at 3000g for 10 min at 4 C. Protein con-
tents of each sample were measured using a modiﬁed Lowry
method [16] with Dc protein assay reagent (Bio-Rad Laboratories,
Inc.) with bovine serum albumin as a standard. For PrPres detection,
cell lysate containing the same protein amount was treated with
10 lg/ml of proteinase K for 30 min at 37 C, and PrPres was pel-
leted by centrifugation at 20 000g for 20 min at 4 C. After dena-
turation in sample buffer by heating at 95 C for 10 min, PrP was
separated using SDS–PAGE and then transferred onto Immobilon-
P membrane (Millipore Corp., Bedford, MA, USA). Subsequently,
PrP was detected using a monoclonal antibody SAF83 as a primary
antibody, which recognizes residues 126–164 of mouse PrP
(1:5000; SPI-Bio, Massy, France), and an alkaline phosphatase-con-
jugated goat anti-mouse antibody (1:20 000; Promega Corp., Mad-
ison, WI, USA) as a secondary antibody. Immunoreactivity was
visualized using CDP-Star detection reagent (Amersham, Piscata-
way, NJ, USA) and was analyzed densitometrically using the ImageJ
program (National Institutes of Health, Bethesda, MD, USA). To
check the sample integrity, protein levels of GAPDH and b-actin
were analyzed in the same samples used for PrPres detection.
2.7. Quantiﬁcation of mRNA level
Cells were lysed with RNAiso-plus reagent (Takara Bio Inc.). To-
tal RNA was extracted using FastPure RNA (Takara Bio Inc.). Poly A+
RNA was puriﬁed from total RNA using an isolation kit (MicroFast
Track MAG micro mRNA; Invitrogen Corp.). In addition, cDNA was
synthesized with ﬁrst strand cDNA synthesis kit (Takara Bio Inc.).
The mRNA level was measured by real-time PCR using SYBR Pre-
mix Ex Taq II (Takara Bio Inc.) or using TaqMan probe with gene
expression assay master mix for gabrb1 (Mm00433461_m1; Ap-
plied Biosystems). Fold change of gene expression was calculated
using the 2DDCt method, with GAPDH as an internal control.
2.8. Statistical analyses
Statistical signiﬁcance was analyzed using one-way analysis of
variance followed by the Tukey–Kramer post-hoc test for multiple
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isons. Statistical signiﬁcance for each analysis was deﬁned as
P < 0.05.
3. Results
3.1. Effects of gabrb1 gene silencing
Gene silencing of gabrb1 in ScN2a cells by transfection of shRNA
expression vector targeting at nucleotides 663–683 of gabrb1 cod-
ing sequence demonstrated a signiﬁcant decrease in both gabrb1
mRNA level (Fig. 1a) and PrPres formation (Fig. 1b). On the other
hand, the PrP mRNA level increased signiﬁcantly (Fig. 1a); upregu-
lation in PrPc protein level was conﬁrmed in uninfected N2a cells
as well as ScN2a cells (Fig. 1a and c). Similar results were also ob-
served in the gene silencing experiment using double-stranded
siRNA, which was designed to target at nucleotides 820–844 of
gabrb1 coding sequence (Fig. 1d–f). Protein levels of GAPDH and
b-actin in the cells treated with the gabrb1 shRNA or siRNA were
consistent with those of the mock controls (Fig. 1b and e), indicat-0
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Fig. 1. Effects of gabrb1 gene silencing. Data from ScN2a cells transfected with shRNA
immunoblot and protein level of PrPres and total PrP (b). Immunoblot and protein level
shown in (c). Data from ScN2a cells transfected with double-stranded siRNA or transfecti
PrP (d); mRNA level of gabrb1 and PrP (e). Immunoblot and protein level of PrPc from N2
are shown in (f). Molecular size markers in the right side of the immunoblots are shown in
data shown here are the average and standard deviation from results of independent tring that the reduction of PrPres level was not attributable to either
sample preparation artifacts or cell viability difference. On the
other hand, in comparison with ScN2a cells, N167 cells showed a
less remarkable decrease in PrPres formation when treated with
the gabrb1 siRNA (Supplementary Fig. 1).
Other representative subunits of GABAA receptor, including b3
and one of its transcript variants, as well as a5, c2, and d, were
subjected to gene silencing experiments in ScN2a cells, but no
modiﬁcation in the PrPres level was observed despite marked
reduction in mRNA levels of the target genes (Supplementary
Fig. 2). These subunits were chosen from the following facts. Most
GABAA receptors contain two a subunits, two b subunits, and
either one c subunit or one d subunit [8]. The a5 subunit is report-
edly upregulated in the brain when prion is inoculated into the
mice expressing anchorless PrP [17]. The b3 subunit is the most
abundant b subunit observed in ScN2a (data not shown). The c2
subunit is the most abundant subunit in the brain and is incorpo-
rated in most GABAA receptor subtypes [18]. The d subunit com-
prises only one member. In addition to the subunits described,
the b2 subunit was also examined in this study, but its gene silenc-0
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of PrPc from N2a cells transfected with shRNA expression vector or mock vector are
on reagent only (mock) are shown: immunoblot and protein level of PrPres and total
a cells transfected with double-stranded siRNA or transfection reagent only (mock)
kilodaltons. Immunoblot data shown here are representative examples; the graphic
iplicate experiments (*P < 0.05, **P < 0.01).
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sion level in ScN2a cells.
3.2. Rescue of gene silencing effect
To conﬁrm the speciﬁcity of gabrb1 gene silencing, a rescue
experiment was performed using an expression vector for the mu-
tated gabrb1 gene, which contained silent mutations at the target-
ing region of the double-stranded siRNA. Introduction of this
mutated gabrb1 gene into ScN2a cells did not modify the PrPres le-
vel (Fig. 2; lanes 1 and 2). Co-transfection of the mutated gabrb1
expression vector and the double-stranded siRNA into ScN2a cells
caused no reduction of the PrPres level, although co-transfection of
the mock expression vector and the double-stranded siRNA caused
substantial reduction in the PrPres level (Fig. 2; lanes 3 and 4). Con-0
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Fig. 2. Rescue of gabrb1 gene silencing. Immunoblot and protein level of PrPres
from ScN2a cells transfected with silent mutation-containing gabrb1 expression
vector (rescue +) or mock vector (rescue ) in the presence of (siRNA +) or the
absence of (siRNA ) the siRNA used in the experiment shown in Fig. 1. Molecular
size markers in the right side of the immunoblots are shown in kilodaltons.
Immunoblot data shown here are representative examples; the graphic data shown
here are the average and standard deviation from results of independent triplicate
experiments (*P < 0.05, **P < 0.01).
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Fig. 3. Effects of gabrb1-speciﬁc inhibitor and GABAA receptor antagonist. Immunoblot
salicylidene salicylhydrazide (a) or GABAA receptor antagonist bicuculline methiodide (b
in kilodaltons. Immunoblot data shown here are representative examples; the graphic d
triplicate experiments (*P < 0.05, **P < 0.01).sequently, the gabrb1 gene silencing effect on the PrPres formation
was rescued by the expression of the silent mutation-containing
gabrb1 gene.
3.3. Effects of GABAA receptor-related compounds
Salicylidene salicylhydrazide is a selective inhibitor of b1 sub-
unit-containing GABAA receptors [19]. Treatment of ScN2a cells
with this compound inhibited PrPres formation dose-dependently
with a 50% inhibition dose of 450 nM (Fig. 3a). However, it did not
modify the PrP mRNA level and the PrPc level, as demonstrated in
the experiment using N2a cells (Supplementary Fig. 3). Another
GABAA receptor antagonist, bicuculline methiodide [8], was also
effective in inhibiting the PrPres formation dose-dependently but
at almost a thousand times higher dose than that of salicylidene
salicylhydrazide (Fig. 3b). No other GABAA receptor-related com-
pound modiﬁed the PrPres level in ScN2a cells (Supplementary
Fig. 4). The compounds tested in this study included an antagonist,
picrotoxin [8], and agonists such as GABA [8], muscimol [8], pento-
barbital [8], ethanol [20], and isoguvacine hydrochloride [21].
4. Discussion
Results show that gabrb1 is involved in the PrPres formation in
ScN2a cells. The PrPres level was reduced signiﬁcantly by gabrb1
gene silencing using either shRNA or siRNA, designed to target
each different region of the gene. This gabrb1 gene silencing effect
was rescued by co-transfection of silent mutation-containing gab-
rb1 gene, which was designed not to be targeted by the siRNA.
Moreover, the results of the experiment with gabrb1-speciﬁc
inhibitor salicylidene salicylhydrazide were coincident with those
of gabrb1 gene silencing experiments. These results indicate that
gabrb1 gene silencing effects are not artifacts such as off-targeting.
We conﬁrmed the gabrb1 gene silencing effects in the mRNA level
but not in the protein level. We attempted unsuccessfully to detect
gabrb1 in protein level using several gabrb1-speciﬁc antibodies ob-0    100  200  300  400  500   (μM)
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) are shown. Molecular size markers in the right side of the immunoblots are shown
ata shown here are the average and standard deviation from results of independent
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very low expression level of gabrb1 protein in the cells and to tech-
nical difﬁculties in distinguishing gabrb1 signals from immuno-
globulin heavy chain signals on the blot. Successful detection of
endogenous gabrb1 protein in immunoblotting from cultured cells
has not been reported.
Gene silencing of other GABAA receptor subunits tested in this
study did not affect the PrPres formation in ScN2a cells, suggesting
that gabrb1 involvement in the PrPres formation is in a manner
irrespective of GABAA receptor. Results from treatments of ScN2a
cells with an antagonist picrotoxin and agonists such as GABA,
muscimol, pentobarbital, ethanol, and isoguvacine hydrochloride
were consistent with this hypothesis. No new function of gabrb1
unrelated to GABAA receptors, except gabrb1 homomeric chloride
ion channels, has been reported in the relevant literature. These
homomeric channels, expressed in Xenopus oocytes or A293 cells,
are sensitive to picrotoxin [22,23], but picrotoxin did not affect the
PrPres formation in ScN2a cells. Consequently, gabrb1 function in
ScN2a cells might differ from the homomeric channels, which re-
mains to be evaluated.
The gabrb1 gene silencing increased the PrP mRNA level and
PrPc protein level. It remains unclear how this happened and
whether this resulted from upregulation of PrP gene transcription
or from increased stability of PrP mRNA. However, it is noteworthy
that the formation of PrPres was reduced despite the increased
PrPc expression level. Furthermore, it is noteworthy that treatment
with gabrb1 inhibitor, salicylidene salicylhydrazide, decreased the
PrPres level but did not modify the PrP expression in either the
mRNA level or protein level. The discrepancy between the results
of gabrb1 gene silencing and those of gabrb1 inhibitor might reﬂect
the difference in the mRNA/protein expression level of gabrb1: a
decreased gabrb1 expression level in the gene silencing versus an
unmodiﬁed gabrb1 expression level but functional inhibition in
the inhibitor. However, further study is necessary to elucidate this
speculation.
Compared to ScN2a cells (RML prion-infected N2a cells), N167
cells (22L prion-infected N2a cells) showed less remarkable reduc-
tion of PrPres formation in gabrb1 gene silencing. This gap of gab-
rb1 involvement between ScN2a cells and N167 cells might reﬂect
prion strain difference. Gabrb1 might be more inﬂuential in the
PrPres formation of RML prion strain, than 22L prion strain. How-
ever, we could not exclude possibilities that other factors than
prion strain might be responsible for the gap observed between
the two cells.
Involvement of GABAergic system in the pathogenesis of prion
diseases has been reported [9–15]. The GABAergic neurons are
degenerated in an early stage of the disease [13,14]. On the other
hand, Triﬁlo and colleagues [17] report upregulation of GABAA
receptor subunits in the prion-inoculated mouse brains expressing
anchorless PrP. According to their speculation, inhibitory synaptic
transmission is over-stimulated while PrPres formation is pro-
moted; then the inhibitory synaptic transmission system collapses
from overwork. Taken together with the ﬁndings in this study, sup-
pression of gabrb1 function by inhibitors or other means might be
useful for both calming overwhelmed GABAergic systems and
inhibiting PrPres formation when conducted at an appropriate
stage of the disease.
In conclusion, we identiﬁed gabrb1 as a new host factor in-
volved in the PrPres formation in ScN2a cells. Although gabrb1 is
a subunit of GABAA receptors, our results suggest that gabrb1 acts
on the PrPres formation in a GABAA receptor-independent manner.
Because previous literature has not revealed any association of
gabrb1 with PrPc [24–30], gabrb1 might function through other
cellular factors or directly interact with PrPres as observed in the
prion-inoculated mouse brains expressing anchorless PrP [17],
where direct association of GABAA receptors with PrPres was dem-onstrated. The mechanism of gabrb1 involvement in the PrPres for-
mation remains to be elucidated.
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